1229 related articles for article (PubMed ID: 17697742)
21. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis.
Wang P; Song JH; Song DK; Zhang J; Hao C
Cell Signal; 2006 Sep; 18(9):1528-35. PubMed ID: 16442262
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
24. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.
Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257
[TBL] [Abstract][Full Text] [Related]
25. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
[TBL] [Abstract][Full Text] [Related]
26. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM
Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816
[TBL] [Abstract][Full Text] [Related]
27. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
Coscia M; Pantaleoni F; Riganti C; Vitale C; Rigoni M; Peola S; Castella B; Foglietta M; Griggio V; Drandi D; Ladetto M; Bosia A; Boccadoro M; Massaia M
Leukemia; 2011 May; 25(5):828-37. PubMed ID: 21372840
[TBL] [Abstract][Full Text] [Related]
28. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin.
Schultze K; Böck B; Eckert A; Oevermann L; Ramacher D; Wiestler O; Roth W
Apoptosis; 2006 Sep; 11(9):1503-12. PubMed ID: 16820965
[TBL] [Abstract][Full Text] [Related]
29. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.
Kaminskyy VO; Surova OV; Vaculova A; Zhivotovsky B
Carcinogenesis; 2011 Oct; 32(10):1450-8. PubMed ID: 21771726
[TBL] [Abstract][Full Text] [Related]
30. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
[TBL] [Abstract][Full Text] [Related]
31. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
[TBL] [Abstract][Full Text] [Related]
32. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
[TBL] [Abstract][Full Text] [Related]
33. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
35. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.
Palacios C; Yerbes R; López-Rivas A
Cancer Res; 2006 Sep; 66(17):8858-69. PubMed ID: 16951203
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
[TBL] [Abstract][Full Text] [Related]
37. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
38. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.
Scielzo C; Ghia P; Conti A; Bachi A; Guida G; Geuna M; Alessio M; Caligaris-Cappio F
J Clin Invest; 2005 Jun; 115(6):1644-50. PubMed ID: 15931393
[TBL] [Abstract][Full Text] [Related]
39. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells.
Santini V; Gozzini A; Scappini B; Caporale R; Zoccolante A; Rigacci L; Gelardi E; Grossi A; Alterini R; Ferrini PR
Haematologica; 1999 Oct; 84(10):897-904. PubMed ID: 10509037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
